Diagnosis of Transthyretin Amyloid Cardiomyopathy

Adam S. Hafeez, Anthony A. Bavry

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Transthyretin amyloid cardiomyopathy (ATTR-CM) continues to be an easily overlooked, life-threatening, yet treatable cause of heart failure. Furthermore, its elusive diagnosis leads to late or misdiagnosis. As therapeutic advancements such as tafamidis usher in a promising new era in the management of ATTR-CM, the need for disease awareness and efficient diagnostic evaluation is crucial. With newer inexpensive imaging modalities and techniques, such as longitudinal strain imaging, T1 mapping on cardiac magnetic resonance imaging, and cardiac scintigraphy, the diagnosis of ATTR-CM no longer requires invasive evaluation with tissue biopsy. Here, the authors review current diagnostic tools to help clinicians diagnose ATTR-CM.

Original languageEnglish (US)
Pages (from-to)85-95
Number of pages11
JournalCardiology and Therapy
Issue number1
StatePublished - Jun 1 2020
Externally publishedYes


  • Amyloidosis
  • Cardiac scintigraphy
  • Cardiomyopathy
  • Diastolic dysfunction
  • Transthyretin amyloid

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Diagnosis of Transthyretin Amyloid Cardiomyopathy'. Together they form a unique fingerprint.

Cite this